Sorting hidden patterns in nanoparticle performance for glioblastoma using machine learning algorithms

Int J Pharm. 2021 Jan 5:592:120095. doi: 10.1016/j.ijpharm.2020.120095. Epub 2020 Nov 18.

Abstract

Cationic compounds have been described to readily penetrate cell membranes. Assigning positive charge to nanosystems, e.g. lipid nanoparticles, has been identified as a key feature to promote electrostatic binding and design ligand-based constructs for tumour targeting. However, their intrinsic high cytotoxicity has hampered their biomedical application. This paper seeks to establish which cationic compounds and properties are compelling for interface modulation, in order to improve the design of tumour targeted nanoparticles against glioblastoma. How can intrinsic features (e.g. nature, structure, conformation) shape efficacy outcomes? In the quest for safer alternative cationic compounds, we evaluate the effects of two novel glycerol-based lipids, GLY1 and GLY2, on the architecture and performance of nanostructured lipid carriers (NLCs). These two molecules, composed of two alkylated chains and a glycerol backbone, differ only in their polar head and proved to be efficient in reversing the zeta potential of the nanosystems to positive values. The use of unsupervised and supervised machine learning (ML) techniques unraveled their structural similarities: in spite of their common backbone, GLY1 exhibited a better performance in increasing zeta potential and cytotoxicity, while decreasing particle size. Furthermore, NLCs containing GLY1 showed a favorable hemocompatible profile, as well as an improved uptake by tumour cells. Summing-up, GLY1 circumvents the intrinsic cytotoxicity of a common surfactant, CTAB, is effective at increasing glioblastoma uptake, and exhibits encouraging anticancer activity. Moreover, the use of ML is strongly incited for formulation design and optimization.

Keywords: Glioblastoma; Glycerol-based cationic lipids; Machine learning; Nanostructured lipid carriers; Neural networks.

MeSH terms

  • Algorithms
  • Drug Carriers / therapeutic use
  • Glioblastoma* / drug therapy
  • Humans
  • Machine Learning
  • Nanoparticles*
  • Nanostructures*
  • Particle Size

Substances

  • Drug Carriers